Riskpilot← Back to searchSign inGet full accessBIOFIELDS HOLDING ApS
APSActiveCVR 10039118Niels Ebbesens Vej 31Other financial service activities, except insurance and pension funding n.e.c. · NACE 6499Est. 2000— employees
Revenue 2024
DKK -9K
+18% vs 2023
EBITDA margin
100.0%
-18% vs 2023
Equity ratio
10.2%
Financial strength
Net profit 2024
DKK -4K
-39% vs 2023
| Revenue | DKK -9K | +18% |
| EBITDA | DKK -9K | -18% |
| Net profit | DKK -4K | -39% |
| Total assets | DKK 716K | +3% |
| Equity | DKK 73K | -6% |
| Employees | — | — |
Legal name
BIOFIELDS HOLDING ApS
CVR number
10039118
Legal form
Anpartsselskab
NACE code
6499 · Other financial service activities, except insurance and pension funding n.e.c.
Founded
1. juli 2000
Share capital
DKK 164.650
Employees
—
VAT registered
No
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktionen.
Company purpose
Selskabets formål er at eje andele, anparter og aktier i selskaber, der udvikler og markedsfører idéer og produkter inden for Biotech-området, særligt med henblik på brug af PEMF-teknologi, samt hermed beslægtet virksomhed
Address
Niels Ebbesens Vej 31
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7 | — | — | — | — | -7 | -7 | -6 | -7 | 33 | -6 | -7 | -9 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 7 | 0 | 0 | 0 | 0 | -7 | -7 | -6 | -7 | 33 | -6 | -7 | -9 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 7 | 0 | 0 | 0 | 0 | -7 | -7 | -6 | -7 | 33 | -6 | -7 | -9 |
| Net financials | -47 | 0 | 0 | 0 | 0 | 4 | -14 | -14 | 621 | 4 | 4 | 4 | 4 |
| Profit before tax | 25 | 0 | 0 | 0 | 0 | -3 | -21 | -20 | 614 | 37 | -2 | -3 | -4 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | 25 | 0 | 0 | 0 | 0 | -3 | -21 | -20 | 614 | 37 | -2 | -3 | -4 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 21 | 0 | 0 | 0 | 0 | 10 | 9 | 9 | 644 | 657 | 675 | 695 | 716 |
| Equity | 413 | 0 | 0 | 0 | 0 | -526 | -547 | -568 | 46 | 83 | 81 | 78 | 73 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 459 | 472 | 487 | 501 | 516 | 532 | 548 | 564 |
| Short-term debt | -433 | 0 | 0 | 0 | 0 | 78 | 84 | 90 | 96 | 58 | 63 | 70 | 79 |
| Total debt | -433 | 0 | 0 | 0 | 0 | 536 | 556 | 577 | 597 | 574 | 594 | 618 | 643 |
EBITDA margin
-887500.0%
This company
15.8%
Market median
-5617189% vs market
20122024
Equity ratio
10.2%
This company
38.2%
Market median
-73% vs market
20122024
Return on equity
-6.1%
This company
18.4%
Market median
-133% vs market
20122024
Net profit margin
-447200.0%
This company
8.1%
Market median
-5521088% vs market
20122024
Asset turnover
-0.01×
This company
1.12×
Market median
-101% vs market
20122024
Debt / equity
8.78×
This company
0.62×
Market median
-1316% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SS Management | Management | 2000 | — | — |
CE | Audit | 2000 | — | — |
PS Management | Management | 2012 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Re5 Holding ApS | Company | 50.0% | 50.0% | 2021 |
Peter Schøller-Larsen Holding ApS | Company | 20.0% | 20.0% | 2021 |
THERAZONE ApS | Company | 10.0% | 10.0% | 2010 |
| Individual | 20.0% | 20.0% | 2006 | |
BEMOLA HOLDING ApS | Company | 20.0% | 20.0% | 2010 |
| Individual | 20.0% | 20.0% | 2006 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Re5 Holding ApS
BIOFIELDS HOLDING ApS Board members of BIOFIELDS HOLDING ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Steen Schierbeck | Management | 0 companies |
| Carl Edvard Gudbergsen | Audit | 0 companies |
| Peter Schøller Larsen | Management | 0 companies |